Epitome Therapeutics

Epitome Therapeutics, a spin-off from EMBL Rome, is developing CADENCE, a next-generation epigenome editing platform. 

CADENCE precisely modulates gene transcription through epigenetic marks without altering DNA, enabling durable, safe, and finely tuned control beyond conventional genome or RNA-based therapies.    

The company focuses on rare and metabolic diseases, leveraging liver-specific gene upregulation with lipid nanoparticle delivery. Founded by experienced biotech professionals and leading scientists, Epitome is positioned at the forefront of advanced precision therapeutics.